Drug intelligence / Profile preview

SNA019

Development stage: Preclinical
Lead developer: SmartNuclide
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

SNA019 is a preclinical-stage therapeutic radiopharmaceutical being developed by SmartNuclide (also known as Suzhou SmartNuclide Biopharmaceutical or Hangzhou Zhihe Dangu Biomedicine). It is designed to target the thyroid-stimulating hormone (TSH) pathway, likely via the thyroid-stimulating hormone receptor (TSHR), for the treatment of solid tumors. As a radiopharmaceutical, SNA019 is intended to deliver targeted ionizing radiation directly to tumor cells expressing the specific target, thereby inducing DNA damage and cell death while minimizing systemic toxicity. The program is currently in the preclinical phase of development.

Targets

TSHR (Thyroid-stimulating hormone receptor)

Beyond the preview

Go deeper on SNA019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNA019.

Explore the full profile